Home » Newsletters » BioWorld Science

BioWorld Science

June 14, 2007

View Archived Issues

Further positive data from M6G phase III trial

Samaritan and UCSD receive grant for neuroprotective work in HIV

Enrollment under way in acute heart failure study of Natrecor

Renovis achieves milestones in VR1 antagonist collaboration with Pfizer

Eisai reviews year of developments

No second administration planned for four-month triptorelin in phase III trial

Kurve Technology and Schering-Plough sign expanded technology agreement

VaxGen and Kaketsuken terminate LC16m8 agreement

Enrollment completed in second phase III study of NGX-4010 for PHN

Snapshots of clinical evaluations of molecular therapeutics for cancer

Clinical data on ipilimumab in melanoma reported at ASCO

Preliminary clinical data on IT-101 in cancer promising

Synairgen reports positive results from asthma and COPD trial

Plevitrexed granted orphan drug status

7TM Pharma initiates phase II clinical study of obinepitide for obesity

Novel oral factor Xa inhibitors profiled at Bayer Healthcare Pharmaceuticals

New diagnostic agents disclosed in recent Hammersmith Imanet patent

Recent Japan Tobacco patent reports novel therapeutic agents for HCV infection

Recent patents disclose novel analgesic agents

Studies detail activity, pharmacokinetics of MK-0974

Snapshots of clinical studies in hematology

Pimavanserin begins phase III for Parkinson's disease psychosis

Altus reacquires rights to ALTU-135 from Dr. Falk Pharma

KB-001 for Pseudomonas infections begins phase I study

Trimesta studied in women with relapsing-remitting MS

BioSante and Teva reinitiate male testosterone therapy development

Kissei and Eisai agree to develop and market Glufast in 10 ASEAN countries

Update on Abbott's chemotherapeutic program

Priority review for oral Hycamtin in SCLC

Rolling NDA commences for Zentase

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...